Arno Therapeutics (ARNI) Stock Statistics & Valuation Metrics
Total Valuation
Arno Therapeutics has a market cap or net worth of $4,984.00. The enterprise value is ―.
- Market Cap
- $4,984.00
- Enterprise Value
- ―
Share Statistics
Arno Therapeutics has 49,350,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,350,000
- Owned by Insiders
- ―
- Owned by Institutions
- 8.47%
Financial Efficiency
Arno Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.00%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 0
- Profits Per Employee
- 0
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Arno Therapeutics is 0.00. Arno Therapeutics’s PEG ratio is ―.
- PE Ratio
- 0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.00
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- ―
Income Statement
In the last 12 months, Arno Therapeutics had revenue of 0 and earned 0 in profits. Earnings per share was 0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- 0
- Pretax Income
- 0
- Net Income
- 0
- EBITDA
- 0
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -7.62M and capital expenditures 0, giving a free cash flow of -7.62M billion.
- Operating Cash Flow
- -7.62M
- Free Cash Flow
- -7.62M
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Arno Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- ―
Stock Price Statistics
- Beta
- -34.46
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 615.78K
Financial Position
Arno Therapeutics as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Arno Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Arno Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.00
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Arno Therapeutics has $2.12M in cash and marketable securities with $5,088.00 in debt, giving a net cash position of $2.12M billion.
- Cash & Marketable Securities
- $2.12M
- Total Debt
- $5,088.00
- Net Cash
- $2.12M
- Net Cash Per Share
- $0.04
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Arno Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
